Answers are grounded in this paper and cite their sources.
Review explores marine-derived compounds' potential as drug leads in various disease areas, suggesting adoption by pharmaceuticals.
The potential of the marine environment to produce candidate compounds (structures) as leads to, or even direct drugs from, has been actively discussed for the last 50 or so years. Over this time frame, several compounds have led to drugs, usually in the area of cancer (due to funding sources). This review is designed to show where there have been successes, but also to show that in a number of disease areas, there are structures originally isolated from marine invertebrates and free-living microbes that have potential, but will need to be "adopted" by pharmaceutical houses in order to maximize their potential.
No takes yet. Share an insight, caveat, or question.
Newman et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: